Literature DB >> 28265719

Health state utility values and patient-reported outcomes before and after vertebral and non-vertebral fractures in an osteoporosis clinical trial.

T Imai1, S Tanaka1, K Kawakami2, T Miyazaki3, H Hagino4, M Shiraki5.   

Abstract

We assessed the health state utility value (HSUV) reductions associated with vertebral fractures using data collected in the Japanese Osteoporosis Intervention Trial-03 (JOINT-03). Our analysis revealed that assessment of HSUVs after morphometric vertebral fracture is important to capture the burden of vertebral fractures.
INTRODUCTION: Evaluation of the HSUV after fracture is important to calculate the quality-adjusted life years (QALYs) of osteoporosis patients, which is essential information in the context of health economic evaluation.
METHODS: JOINT-03 study patients were aged ≥65 years and treated with risedronate and vitamin K2 or risedronate alone. Radiographic information and patient-reported outcomes measured by EQ-5D and a visual analogue scale (VAS) were assessed at registration and followed up after 6, 12, and 24 months. According to differences among the dates of these assessments and the radiographic information, we classified the follow-up HSUVs calculated based on EQ-5D results into before or after fracture categories regardless of clinical symptoms.
RESULTS: Among 2922 follow-up HSUVs, 201 HSUVs were categorized as HSUVs that were observed after incident vertebral fractures on X-ray films. The median time from the detection of an incident vertebral fracture until the EQ-5D assessment was 53 days (25th percentile, 0 day; 75th percentile, 357 days). The impact of incident vertebral fractures on HSUVs was quantified as -0.03. Among the five health profile domains on the EQ-5D, an incident vertebral fracture had significant effects on anxiety/depression, self-care, and usual activities.
CONCLUSIONS: The results suggest that incident morphometric vertebral fracture was associated with impairment of the HSUV for patients with osteoporosis not only immediately but also several months after the fracture.

Entities:  

Keywords:  Health economics; Health state utility value; Morphometric vertebral fracture; Osteoporosis; Radiographic assessment

Mesh:

Substances:

Year:  2017        PMID: 28265719     DOI: 10.1007/s00198-017-3966-7

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  35 in total

Review 1.  A systematic review and meta-analysis of utility-based quality of life for osteoporosis-related conditions.

Authors:  L Si; T M Winzenberg; B de Graaff; A J Palmer
Journal:  Osteoporos Int       Date:  2014-02-22       Impact factor: 4.507

2.  Modelling the cost effectiveness of interventions for osteoporosis: issues to consider.

Authors:  Matt D Stevenson; Peter L Selby
Journal:  Pharmacoeconomics       Date:  2014-08       Impact factor: 4.981

Review 3.  The clinical impact of vertebral fractures: quality of life in women with osteoporosis.

Authors:  D T Gold
Journal:  Bone       Date:  1996-03       Impact factor: 4.398

4.  Underdiagnosis of vertebral fractures is a worldwide problem: the IMPACT study.

Authors:  Pierre D Delmas; Lex van de Langerijt; Nelson B Watts; Richard Eastell; Harry Genant; Andreas Grauer; David L Cahall
Journal:  J Bone Miner Res       Date:  2004-12-06       Impact factor: 6.741

5.  Costs and quality of life associated with osteoporosis-related fractures in Sweden.

Authors:  Fredrik Borgström; Niklas Zethraeus; Olof Johnell; Lars Lidgren; Sari Ponzer; Olle Svensson; Peter Abdon; Ewald Ornstein; Karl Lunsjö; Karl Göran Thorngren; Ingemar Sernbo; Clas Rehnberg; Bengt Jönsson
Journal:  Osteoporos Int       Date:  2005-11-09       Impact factor: 4.507

Review 6.  Measuring health-related quality of life.

Authors:  G H Guyatt; D H Feeny; D L Patrick
Journal:  Ann Intern Med       Date:  1993-04-15       Impact factor: 25.391

7.  Undiagnosed vertebral fractures influence quality of life in postmenopausal women with reduced ultrasound parameters.

Authors:  Ranuccio Nuti; Carla Caffarelli; Giuseppe Guglielmi; Luigi Gennari; Stefano Gonnelli
Journal:  Clin Orthop Relat Res       Date:  2014-04-12       Impact factor: 4.176

8.  Sequential change in quality of life for patients with incident clinical fractures: a prospective study.

Authors:  H Hagino; T Nakamura; S Fujiwara; M Oeki; T Okano; R Teshima
Journal:  Osteoporos Int       Date:  2008-10-03       Impact factor: 4.507

9.  The International Costs and Utilities Related to Osteoporotic Fractures Study (ICUROS)--quality of life during the first 4 months after fracture.

Authors:  F Borgström; I Lekander; M Ivergård; O Ström; A Svedbom; V Alekna; M L Bianchi; P Clark; M D Curiel; H P Dimai; M Jürisson; R Kallikorm; O Lesnyak; E McCloskey; E Nassonov; K M Sanders; S Silverman; M Tamulaitiene; T Thomas; A N A Tosteson; B Jönsson; J A Kanis
Journal:  Osteoporos Int       Date:  2013-01-10       Impact factor: 4.507

10.  Denosumab for Elderly Men with Osteoporosis: A Cost-Effectiveness Analysis from the US Payer Perspective.

Authors:  Stuart Silverman; Irene Agodoa; Morgan Kruse; Anju Parthan; Eric Orwoll
Journal:  J Osteoporos       Date:  2015-12-09
View more
  5 in total

Review 1.  Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women.

Authors:  George A Wells; Shu-Ching Hsieh; Carine Zheng; Joan Peterson; Peter Tugwell; Wenfei Liu
Journal:  Cochrane Database Syst Rev       Date:  2022-05-03

2.  Evaluation of pain, quality of life, and patient satisfaction in parenterally treated patients with postmenopausal osteoporosis.

Authors:  Tuğba Özsoy-Ünübol; Gülseren Akyüz; Samaya Mirzayeva; Tuba Güler
Journal:  Turk J Phys Med Rehabil       Date:  2020-02-26

3.  Serum C-C Motif Ligand 11/eotaxin-1 May Serve as a Candidate Biomarker for Postmenopausal Osteoporosis.

Authors:  Wen Wang; Ci-You Huang; Zhuo-Ping Wang; Shan-Shan Xu; Tie-Yong Qian; Yi-Ding Chen; Wei-Guo Wu
Journal:  J Med Biochem       Date:  2019-05-11       Impact factor: 3.402

4.  Validation of the European Quality of Life-5 Dimensions, 3-Level Version (EQ-5D-3L) in Patients With Osteoporotic Vertebral Fracture and Comparing Their Health-Related Quality of Life With That of the General Population in Korea.

Authors:  Je Hoon Jeong; Min-Woo Jo; Dong Kyu Chin; Woo-Seung Son; Minsu Ock; Jung-Kil Lee
Journal:  Korean J Neurotrauma       Date:  2022-04-04

5.  Percutaneous Vertebroplasty and Facet Blocking for Treating Back Pain Caused by Osteoporotic Vertebral Compression Fracture.

Authors:  Yongquan Cheng; Xiaoliang Wu; Jiawei Shi; Hui Jiang
Journal:  Pain Res Manag       Date:  2020-08-11       Impact factor: 3.037

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.